VNA
ZYNE

Valley National Advisers’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Valley National Advisers’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10
Closed – – 874
2020
Q1 		$0 Buy
+10
New +$46 ﹤0.01% 864

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Valley National Advisers's ZYNE Position: Q2 2020 in Review

Valley National Advisers sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 10 shares.

Valley National Advisers first reported a position in ZYNE in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

  • Valley National Advisers reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • Valley National Advisers sold 10 Zynerba Pharmaceuticals, Inc shares in Q2 2020.
  • Valley National Advisers first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2020 and held it in 1 quarter.
  • Valley National Advisers's Zynerba Pharmaceuticals, Inc position peaked at $0 in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on Valley National Advisers's 13F filing for Q2 2020, filed 10 Aug 2020.